Standout Papers

Breast cancer 2011 2026 2016 2021 1.9k
  1. Breast cancer (2019)
    Nadia Harbeck, Frédérique Penault‐Llorca et al. Nature Reviews Disease Primers
  2. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (2011)
    José Baselga, Javier Cortés et al. New England Journal of Medicine
  3. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer (2015)
    Sandra M. Swain, José Baselga et al. New England Journal of Medicine
  4. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study (2011)
    Javier Cortés, Joyce O’Shaughnessy et al. The Lancet
  5. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) (2013)
    Andreas Schneeweiß, Stephen Chia et al. Annals of Oncology
  6. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study (2013)
    Sandra M. Swain, Sung‐Bae Kim et al. The Lancet Oncology
  7. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (2010)
    David Miles, Arlene Chan et al. Journal of Clinical Oncology
  8. Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer (2007)
    Maurizio Scaltriti, Federico Rojo et al. JNCI Journal of the National Cancer Institute
  9. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer (2022)
    Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine
  10. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer (2016)
    María Teresa Herrera-Abreu, Marta Palafox et al. Cancer Research
  11. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer (2017)
    Maura N. Dickler, Sara M. Tolaney et al. Clinical Cancer Research
  12. Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer (2018)
    Tiffany A. Traina, Kathy D. Miller et al. Journal of Clinical Oncology
  13. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial (2021)
    Eric P. Winer, Seock‐Ah Im et al. The Lancet Oncology
  14. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies (2021)
    Paolo Tarantino, Roberto Carmagnani Pestana et al. CA A Cancer Journal for Clinicians
  15. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial (2023)
    Hope S. Rugo, Aditya Bardia et al. The Lancet
  16. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (2022)
    Hope S. Rugo, Aditya Bardia et al. Journal of Clinical Oncology
  17. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial (2022)
    José Manuel Pérez-García, Marta Vaz Batista et al. Neuro-Oncology
  18. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression (2024)
    Aditya Bardia, Hope S. Rugo et al. Journal of Clinical Oncology
  19. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 (2024)
    Lajos Pusztai, Carsten Denkert et al. Annals of Oncology

Immediate Impact

8 by Nobel laureates 19 from Science/Nature 138 standout
Sub-graph 1 of 18

Citing Papers

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Analysis of Breast Cancer Mortality in the US—1975 to 2019
2024 Standout
3 intermediate papers

Works of Javier Cortés being referenced

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 Standout
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
2011 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Javier Cortés 20283 8493 7648 709 27.3k
Mario Campone 14956 8736 6936 532 23.2k
Véronique Dièras 17949 9207 6141 351 22.5k
Luca Gianni 19941 5805 8116 305 29.8k
Giuseppe Curigliano 15507 6025 6811 828 25.2k
Hiroji Iwata 16179 9284 6860 514 22.9k
Seock‐Ah Im 23147 13475 8677 652 31.7k
George W. Sledge 14481 6145 9362 435 24.8k
Masakazu Toi 10580 5860 6747 651 20.9k
Nadia Harbeck 19898 11633 12822 839 32.4k
John Crown 12728 4664 5824 413 19.6k

All Works

Loading papers...

Rankless by CCL
2026